Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
250.2 CHF | +2.46% | +5.21% | -4.28% |
Apr. 19 | Swiss Equities Flash Green; Middle East Tensions Rise | MT |
Apr. 19 | Roche: approval in lung cancer in the United States | CF |
Sales 2024 * | 60.03B 65.76B | Sales 2025 * | 63.55B 69.62B | Capitalization | 182B 199B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.54B | Net income 2025 * | 14.64B 16.04B | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 13.62B 14.92B | Net Debt 2025 * | 7.57B 8.29B | EV / Sales 2025 * | 2.98 x |
P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
12.1
x | Employees | 103,605 |
Yield 2024 * |
4.28% | Yield 2025 * |
4.44% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +2.61% | ||
1 week | +0.66% | ||
Current month | +0.49% | ||
1 month | +3.04% | ||
3 months | -8.06% | ||
6 months | -3.48% | ||
Current year | -6.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 95-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.06% | 2 M€ | -.--% | - | |
2.06% | 2 M€ | +9.19% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 250.2 | +2.46% | 49 108 |
24-04-22 | 244.2 | +2.61% | 41,027 |
24-04-19 | 238 | +0.51% | 21,595 |
24-04-18 | 236.8 | -0.25% | 27,764 |
24-04-17 | 237.4 | -0.17% | 28,903 |
Delayed Quote Swiss Exchange, April 22, 2024 at 11:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.46% | 659B | |
+25.38% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.13% | 215B | |
+2.93% | 210B | |
-8.79% | 149B | |
-5.59% | 146B |
- Stock Market
- Equities
- ROG Stock
- RO Stock